Equity Overview
Price & Market Data
Price: $0.29
Daily Change: -$0.0118 / 4.07%
Range: $0.271 - $0.32
Market Cap: $1,813,478
Volume: 694,382
Performance Metrics
1 Week: 14.87%
1 Month: -22.88%
3 Months: -68.04%
6 Months: -77.20%
1 Year: -90.50%
YTD: -65.77%
Company Details
Employees: 9
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. The company is developing Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas; and SP-2-225, a pre-clinical class IIb product candidate that effects on the regulation of the immune system. It is also developing SP-1-303, a pre-clinical selective Class I HDAC for use in the treatment of ER positive breast cancers; and SP-1-161, a HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway. The company was founded in 2012 and is headquartered in Gaithersburg, Maryland.